"The most advanced aesthetic medicine available. Also the most personal. It is, by definition, Self."
Your patients' own living fat — 85–95% cell viability, active stem cells, zero rejection risk — processed at our HTA-licensed GMP facility. Returned as quality-certified 5ml aliquots. Ready to inject. No post-thaw wash. Permanent results. Not available from medspas or injectables clinics. By design.
This is not a speculative market thesis. It is what you are already seeing in your consultation room. The data and the peer-reviewed literature are now confirming what experienced surgeons have been observing clinically for the past three years.
Patients with filler fatigue, patients exiting GLP-1 programmes, patients who declined HA and have been waiting for something genuinely natural — none of them can be served by a medspa. All of them are walking into your consultation room. The autologous fat grafting you are already performing, enhanced by T&CT's banking and processing platform, is the answer they have been looking for. The clinical skills already exist. The patient demand already exists. What was missing was the infrastructure to make it a repeatable, scalable, bankable programme rather than a one-off surgical procedure.
Regenerys Self® is that infrastructure.
Micro-fat grafting, Coleman technique, perioral fat injection, nano-fat for skin quality — every leading aesthetic plastic surgeon is already offering some version of autologous fat as an alternative or complement to synthetic fillers. Regenerys Self® is not asking you to learn a new procedure. It is asking you to apply the skills you have to a banked, processed, certified starting material — and to offer your patients a programme rather than a single procedure.
The Coleman technique for structural facial fat grafting is standard in your practice. You know the anatomy, the cannula sizing, the layered approach to cheek, temple, and jawline restoration.
You are already performing micro-fat injections at the lip base, perioral, and vermilion body — increasingly promoted as a more permanent, natural alternative to the synthetic lip filler cycle your patients are trying to exit.
Emulsified nano-fat and stromal vascular fraction are part of your advanced toolkit — improving skin texture, tone, and quality through the paracrine biology of the patient's own adipose-derived growth factors.
Fat placement in and around scar tissue — for post-surgical, post-oncological, and contour irregularity correction — is well within your standard skill set. The biological activity of live fat in these contexts is clinical evidence you already cite.
Same-day grafting requires a new liposuction every session. Regenerys Self® takes 100–150 ml once and produces 16–24 certified aliquots. No repeat harvest. No repeat liposuction. Your patient returns for injection appointments, not surgical procedures.
Fresh same-day aspirate that is centrifuged and immediately reinjected typically achieves 25–30% viable cell retention. T&CT's proprietary cryopreservation preserves 85–95%. You are injecting three to four times more live cells per aliquot than same-day grafting provides.
Aliquots are prepared by T&CT to your specified application — structural macro-fat, Coleman micro-fat, or emulsified nano-fat. The correct particle size for your clinical intent arrives processed, certified, and ready. You do not process in-clinic.
Every aliquot arrives with a viability and sterility certificate — something no same-day autologous procedure can provide. You can show your patient documentary evidence of what you are injecting. That is a clinical and medico-legal distinction that matters.
"Everything you are already doing with autologous fat — except the fat arrives having been properly processed, properly certified, and properly stored. And your patient only has to go through the harvest once."
When you instruct T&CT on a patient's aliquot order, you specify the preparation type for each aliquot. We process to your clinical intent and certify each preparation independently. The fat that arrives at your clinic is not generic aspirate — it is prepared, particle-sized, and certified for the specific application you have planned.
Clinical and medico-legal note: The quality certificate constitutes contemporaneous documentary evidence of what was injected, at what viability, and at what preparation specification. In the evolving medico-legal environment around injectable complications, this documentation provides a level of traceability and clinical defensibility that same-day autologous procedures categorically cannot offer.
This page is for qualified plastic surgeons and advanced filler specialists. Full commercial model and fee structure are available after practitioner verification below. More information on the complete T&CT platform at tissueandcell.tech ↗
Regenerys Self® gives your practice access to the first commercially structured autologous fat banking programme for injectable use. T&CT handles all processing, quality certification, cryogenic banking, and logistics. You handle the harvest and injection — using skills you already have for Phase 1 treatments.
Regenerys Self® is not available at injectables clinics or medspas. It is not available from non-surgical practitioners. It requires the clinical skills to perform tumescent micro-liposuction and fat injection under local anaesthetic — skills that belong to qualified surgeons and advanced specialists. By offering Regenerys Self®, your practice offers something the commoditised injectable market categorically cannot. It brings clinical qualification back into the equation precisely where patients increasingly demand it.
85–95% post-thaw cell viability versus the industry standard of 25–30% — and versus 0% for every synthetic or cadaveric product including Alloclae. Every aliquot carries a viability and sterility certificate. No post-thaw wash step required. Processing in Dallas (US) or Sheffield (UK/EU/Middle East).
Not available from injectables shops or medspas. The programme requires surgical and procedural competence. That distinction matters to patients and to your practice positioning.
100–150 ml tumescent micro-liposuction under local anaesthetic. Standard capability for any plastic or aesthetic surgeon. No specialist equipment required beyond existing liposuction capability.
Coleman or modified fat grafting technique. Any surgeon performing facial fat grafting already has this competency for Phase 1 treatments. Additional T&CT training for perioral and nano-fat Phase 2 applications.
Standard non-exclusive partnership agreement governing commercial structure, quality obligations, and patient consent requirements. Typically 2–4 weeks from expression of interest to execution.
T&CT provides standardised consent framework meeting HTA and FDA requirements. Chain-of-custody documentation provided with every collection kit. Not to be modified without T&CT approval.
T&CT dispatches a collection kit per patient. Aspirate placed in provided container at harvest, prepared for same-day courier. No specialist cold-chain equipment required at the practice.
Pre- and post-treatment photography at every session per T&CT protocol. The programme's clinical reputation is built on photographic evidence. This is commercially essential, not optional.
Full procedural documentation provided to registered partner surgeons. Note: on patient-facing materials the term "dose" (5ml) is used rather than aliquot.
Standard tumescent solution (1:1,000,000 adrenaline in saline, 0.1% lidocaine). Allow 15–20 minutes for full effect. Infiltration volume 2–3× planned aspirate. The tumescent technique is non-negotiable — minimising blood contamination in the aspirate is a critical quality determinant for the banked sample and post-thaw viability.
3mm blunt-tipped cannula with low-pressure syringe aspiration. Not powered suction for the banking aliquot — mechanical syringe technique required to minimise adipocyte trauma. If combined with standard liposuction for body contouring, collect the 100–150 ml banking aliquot first. Label immediately with patient identifier barcode from collection kit.
Complete chain-of-custody form: T&CT patient account number (not patient name), procedure date/time, aspirate volume, donor site, cannula size, surgeon identifier. Apply tamper-evident seals. All documentation in external document pouch only — no patient-identifiable material inside the package.
Contact the nominated clinical courier (in collection kit) immediately after harvest for same-day collection. Do not freeze the sample — T&CT's process requires fresh aspirate. Insulated packaging maintains 4–8°C during transit. Processing begins within hours of receipt at Dallas or Sheffield.
Aliquots returned frozen in validated cryogenic packaging. Thaw at room temperature 20–30 minutes. No post-thaw wash step required — T&CT's cryoprotectant does not require removal prior to injection, simplifying the return workflow. Inject using standard Coleman technique. Each 5ml aliquot is five times a standard filler syringe.
The nine Regenerys Self® programme treatments represent the commercial core of the programme. They are not the limits of what properly processed, high-viability banked autologous fat can do. The literature documents a broader range of applications — some aesthetic, some therapeutic, some at the boundary of both — where autologous fat is demonstrably superior to HA filler or is the only appropriate injectable material.
These are not primary commercial channels for the current phase of the programme. They are presented here so that partner surgeons have a complete clinical picture, and can identify patients in their existing practice whose needs may be met by banked Self beyond the nine core treatments.
Head-to-head comparative studies confirm fat grafting produces superior grade of improvement and longer-lasting results than HA filler. Critically, autologous fat avoids the Tyndall effect — the bluish discolouration from subcutaneous HA in this zone — while the SVF secretome improves eyelid skin quality and transparency in ways HA cannot. A meta-analysis of over 4,000 cases reports a 90.9% satisfaction rate for periorbital fat grafting. Nano-fat preparation is particularly well-suited to this zone.
Preparation: nano-fat / micro-fat · Technique: specialist periorbital competency requiredHA in the temples requires continuous repetition and carries vascular risk given the proximity of the temporal artery. Autologous fat integrates permanently and eliminates repeat exposure. A 2024 Frontiers in Surgery systematic review identifies autologous fat as increasingly preferred for temporal augmentation, specifically citing the elimination of allergenic potential and the financial burden of ongoing synthetic injections.
Preparation: structural macro-fat · Standard Coleman techniqueFor deep structural folds where volume — not surface filling — is the primary requirement, autologous fat produces permanent structural correction with simultaneous skin quality improvement. Unlike HA in these zones, properly retained fat does not migrate to adjacent planes, does not create the distinctive flat-cast appearance of repeated HA, and improves the overlying skin progressively over 12–24 months via ADSCs.
Preparation: micro-fat (nasolabial) / nano-fat (superficial perioral) · Existing skillThe nose is the highest-risk site for vascular occlusion complications from HA injection — with documented cases of blindness and tissue necrosis in the published literature. Autologous fat injection for nasal contour correction, saddle deformity, radix refinement, and post-rhinoplasty irregularities carries a fundamentally different risk profile. Fat placed at the periosteum integrates with the nasal soft tissue envelope; it does not embolise. For rhinoplasty-trained surgeons, this is a natural extension of existing competency.
Preparation: micro-fat / nano-fat · Rhinoplasty-trained surgeons onlyEarlobes lose the natural fat pad with age, becoming elongated and unable to support jewellery. HA is used but produces temporary results in a small soft-tissue environment where repeated injections accumulate risk. Autologous micro-fat restores the natural pad permanently. For atrophic acne scars, published evidence confirms fat grafting not only lifts the contour but progressively improves pigmentation and surface texture — an outcome HA cannot produce.
Preparation: micro-fat · Low-volume applications from existing banked supplyHA injected superficially into the neck and décolletage occupies space temporarily. Nano-fat and SVF-enriched preparations deliver continuous growth factor signalling to sun-damaged, thin, collagen-depleted skin — driving genuine structural remodelling rather than temporary hydration. The SVF secretome activates fibroblasts and drives collagen synthesis in a tissue environment that does not respond to volume placement alone.
Preparation: nano-fat · SVF-enriched fraction · Intradermal and subdermal deliveryRadiodermatitis was historically considered irreversible. Since Rigotti et al.'s landmark 2007 paper, autologous fat grafting has been confirmed in multiple studies to actively reverse the histological changes of radiation injury — including neovessel formation, new collagen synthesis, dermal hyperplasia, and local hypervascularity. These are not volumising effects. No synthetic filler has any mechanism to drive this biological reversal. This is a therapeutic application with clinical evidence of real tissue regeneration.
Clinical territory: radiation oncology / plastic surgery · Referral channel · T&CT specialist protocolA published clinical study of 16 SSc patients reported statistically significant improvements in mouth opening capacity, MHISS and Rodnan skin sclerosis scores (p <0.001) following autologous fat injection. Digital applications have confirmed new capillary bed formation in patients with debilitating digital ulcers. The mechanism — ADSC-driven reduction of collagen deposition, increased elasticity and angiogenesis — is pharmacologically specific to living autologous fat. HA filler placed in fibrotic scleroderma tissue does nothing to modify the disease process.
Clinical territory: rheumatology / specialist plastic surgery · Referral channelHIV lipoatrophy is a metabolic failure of adipocyte function — not simply volume loss — driven by antiretroviral toxicity. A systematic review comparing HA/PLLA fillers with autologous fat transfer concluded that fat transfer offers similar to superior long-term durability with lower financial burden. The regenerative biology of transplanted healthy adipocytes addresses the tissue environment in ways that no synthetic volumising agent can, and the absence of repeat foreign material injections is clinically and practically important in an immunocompromised population.
Clinical territory: HIV medicine / infectious disease / plastic surgery · Referral channelParry-Romberg causes progressive unilateral atrophy of skin, fat, muscle, and bone. HA filler is used by some practitioners but must be repeated indefinitely as the condition progresses — accumulating cumulative risk in a young patient population. Autologous fat, implicitly preferred in the literature over non-autologous injectables, offers the additional potential that the immunomodulatory properties of ADSCs may moderate the disease process itself — not merely replace the tissue it destroys. This remains an area of active investigation.
Clinical territory: rare disease / paediatric plastic surgery · T&CT case-by-case protocolAutologous fat grafting for burn scar contracture release is a well-established application in the plastic surgery literature — reducing tethering, improving elasticity and suppleness, and softening the surface through ADSC-driven tissue remodelling. This is not a filler application. It is a therapeutic procedure that uses the regenerative biology of living fat to modify scar tissue that synthetic products cannot touch. Published evidence confirms both pain relief and functional improvement in addition to cosmetic improvement.
Clinical territory: burns / reconstructive plastic surgery · T&CT specialist protocolEvery application in both tiers benefits from the same thing: high-viability banked autologous fat — specifically the 85–95% post-thaw cell viability that T&CT's proprietary cryopreservation delivers. The retention problems historically associated with same-day fat grafting were primarily a viability problem. That problem is solved. The clinical applications that flow from that solution are not limited to nine.
For Tier 2 applications — radiodermatitis, scleroderma, HIV lipoatrophy, Parry-Romberg, burn scar — T&CT operates a case-by-case clinical consultation pathway. These are not handled through the standard commercial programme. Contact the T&CT clinical team directly to discuss eligibility, preparation specification, and the applicable clinical protocol.
Contact clinical team →The full commercial model — including channel fee percentages, per-aliquot economics, and the detailed practice P&L — is available to verified registered practitioners only. Enter your GMC or medical licence number to access.
Commercial fee and pricing information is available to registered plastic surgeons and advanced filler specialists only. Enter your GMC / medical licence number to access.